

# **Inborn Errors of Metabolism**

*(For Master degree)*

**By**

**Ahmed M. Badr (MD)**

**Assistant Professor of Pediatrics**

**Cairo University**

**2013**

# Inborn Errors of Metabolism

## Definition

- Group of inherited biochemical disorders caused by enzyme, coenzyme, receptor, membrane or transport defect

## Presentation

- Variable severity [Mild-Severe-Lethal]
- Variable age of onset

## Biochemical Defect

### A) Enzyme Defects

**Enzymes:** Biological catalysts. Virtually all enzymes are proteins (either simple or conjugated). Conjugated enzyme (holoenzyme) = Apoenzyme + Coenzyme

**Apoenzyme:** It is the protein part of the holoenzyme

**Coenzyme:** It is the organic non-protein part of the holoenzyme (e.g., vitamin...)

**Enzyme defect** leads to metabolic block:

- Accumulation of precursors

Disease	Enzyme Defect	Accumulated substance
Galactosemia	Galactose 1-P-uridyltransferase	Galactose & Galactitol
GSD ( <i>Von Gierke</i> )	Glucose 6-Phosphatase	Glycogen
Gaucher	Glucocerebrosidase ( $\beta$ -Glucosidase)	Glucocerebrosides (glycolipid)
Niemann-Pick	Sphingomyelinase	Sphingomyeline
MPS ( <i>Hurler</i> )	$\alpha$ -L- Iduronidase	GAG = Glycosaminoglycan
GM <sub>1</sub> Gangliosidosis	$\beta$ -Galactosidase	Gangliosides
GM <sub>2</sub>	Tay-Sachs	Hexosaminidase A
	Sandhoff	Hexosaminidase A & B

- Deficiency of end-product

Albinism: ( $\downarrow\downarrow$  Melanin) Tyrosine  $\xrightarrow{\text{Tyrosinase}}$  Melanin

- Opening of alternative pathway

Normally: Phenylalanine  $\xrightarrow{P.\text{hydroxylase}}$  Tyrosine  
 Phenylketonuria:  $\uparrow\uparrow$  Phenylalanine  $\longrightarrow$   $\uparrow\uparrow$  Phenylpyruvate, lactate & acetate

### B) Transport across cell membranes

- Transport across cell membrane

Specific vitamin B<sub>12</sub> malabsorption due defective receptors for IF-B<sub>12</sub> complex

- Transport across lysosomal membrane

Cystinosis: Trapping of cystine inside the lysosomes. [Action of Cysteamine??]

### C) Binding Proteins

- Hemoglobin carries O<sub>2</sub>: HbM cannot carry O<sub>2</sub>
- Ceruloplasmin carries Copper: Wilson disease



### When to suspect (= Clinical Picture)

1. **Neonatal Presentation:** Poor feeding, lethargy, vomiting, seizures [DD: Sepsis, ↓↓Ca, ↓↓G]
2. **Consanguineous parents & positive family history**
3. **Unexplained MR, coma, convulsions or developmental delay**
4. **Unexplained vomiting, acidosis**
5. **Unexplained organomegaly (Hepatomegaly)**
6. **Unexplained odor:**
  - ☒ **PKU:** Mousy or musty
  - ☒ **Tyrosinemia (& Hypermethioninemia):** Boiled cabbage
  - ☒ **Maple syrup urine:** Maple syrup
  - ☒ **Isovaleric acidemia:** Sweaty foot
  - ☒ **Multiple carboxylase deficiency:** Tomcat urine
7. **Unexplained muscle weakness or cardiomyopathy**
8. **Unexplained renal stones**
9. **Episodic pattern (with disease-free intervals)**



### Neonatal screening (American College of Medical Genetics = ACMG)

	Primary Disorders	Secondary Disorders
<b>Organic acid</b>	<ul style="list-style-type: none"><li>▪ Methylmalonic acidemia</li><li>▪ Propionic acidemia</li><li>▪ Isovaleric acidemia</li><li>▪ Glutaric aciduria type I</li><li>▪ Multiple carboxylase deficiency</li><li>▪ Beta-ketothiolase deficiency</li></ul>	<ul style="list-style-type: none"><li>▪ Malonic acidemia</li></ul>
<b>Fatty acids</b>	<ul style="list-style-type: none"><li>▪ MCAD, VLCAD, LCHAD</li><li>▪ Carnitine uptake defect</li></ul>	<ul style="list-style-type: none"><li>▪ Carnitine palmitoyl transferase I deficiency</li><li>▪ Carnitine palmitoyl transferase II deficiency</li></ul>
<b>Amino acids</b>	<ul style="list-style-type: none"><li>▪ Phenylketonuria</li><li>▪ Maple syrup urine disease</li><li>▪ Homocystinuria</li><li>▪ Citrullinemia</li><li>▪ Argininosuccinic acidemia</li><li>▪ Tyrosinemia (type I)</li></ul>	<ul style="list-style-type: none"><li>▪ Tyrosinemia type II</li><li>▪ Tyrosinemia type III</li></ul>
<b>Hemoglobin</b>	<ul style="list-style-type: none"><li>▪ Sickle cell anemia</li><li>▪ Hemoglobin S-β-thalassemia</li><li>▪ Hemoglobin SC disease</li></ul>	<ul style="list-style-type: none"><li>▪ Hemoglobin variant (Hemoglobin E)</li></ul>
<b>Others</b>	<ul style="list-style-type: none"><li>▪ Congenital hypothyroidism</li><li>▪ Biotinidase deficiency</li><li>▪ Congenital adrenal hyperplasia</li><li>▪ Galactosemia</li><li>▪ Hearing deficiency</li><li>▪ Cystic fibrosis</li></ul>	<ul style="list-style-type: none"><li>▪ Galactose epimerase deficiency</li><li>▪ Galactokinase deficiency</li></ul>

# Treatment of Genetic Diseases

## 1. Enzyme Induction

Phenobarbitone in Crigler-Najjar syndrome type II (AD)

## 2. Enzyme Replacement

- ☒ Gaucher disease
- ☒ Pompe disease (GSD type II)
- ☒ Fabry disease
- ☒ ADA deficiency
- ☒ Some MPS
- ☒ Cystic fibrosis

## 3. Recombinant proteins

- ☒ GH
- ☒ Insulin
- ☒ Factor VIII
- ☒ EPO
- ☒ GM-CSF
- ☒ Interferon

## 4. Replacement of Hormones

- ☒ Hydrocortisone (CAH)
- ☒ 9- $\alpha$  fludrocortisol (CAH)
- ☒ GH (Hypopituitarism)
- ☒ Thyroxine (Congenital hypothyroidism)

## 5. Replacement of vitamins

- ☒ B<sub>1</sub> (Maple syrup urine disease)
- ☒ B<sub>6</sub> (Homocystinuria)
- ☒ B<sub>12</sub> (Methylmalonic acidemia)
- ☒ Biotin (Propionic acidemia)
- ☒ Folic acid (Megaloblastic anemia)
- ☒ Vitamin D (Vitamin D resistant rickets)

## 6. Dietary restriction

- ☒ Maple syrup urine (V I L)
- ☒ Methionine (Homocystinuria)
- ☒ PKU (Phenylalanine)
- ☒ Urea cycle disease (proteins)
- ☒ Galactosemia (galactose, Lactose)
- ☒ Hypercholesterolemia (Lipids)

## 7. Induction of alternative pathways

Na benzoate in urea cycle defects (to eliminate NH<sub>3</sub>)

## 8. Preventive therapy

Avoidance of certain drugs in G6PD deficiency

## 9. BM or liver transplantation

## 10. Portocaval anastomosis

In cases of portal hypertension (GSD type IV)

## 11. Extracorporeal therapy

Plasmapheresis in the Rx of hypercholesterolemia

## 12. Gene therapy (Give examples)



### Note

Essential Amino acids	Non-essential Amino acids
<ul style="list-style-type: none"><li>▪ Phenylalanine</li><li>▪ Valine, leucine, isoleucine</li><li>▪ Threonine, methionine</li><li>▪ Arginine, lysine, histidine</li><li>▪ Tryptophan</li></ul>	<ul style="list-style-type: none"><li>▪ Tyrosine</li><li>▪ Glycine glutamic, glutamine</li><li>▪ Alanine, proline</li><li>▪ Cysteine, serine</li><li>▪ Aspartic, asparagine</li></ul>



# Disorders of Protein Metabolism

## Phenylalanine & Tyrosine



# Phenylketonuria

## Definition

- AR (12q for PAH)
- **Classic PKU:** Plasma phenylalanine level > 20 mg/dL
- **Non-PKU hyperphenylalaninemia:** Plasma phenylalanine level < 20 mg/dL [but > 2 mg/dL]

## Biochemical Defect

- $\downarrow\downarrow$  Phenylalanine hydroxylase  $\rightarrow$   $\uparrow\uparrow$  Phenylalanine  $\rightarrow$  CNS damage (mechanism?)

## Epidemiology

- **Non-PKU hyperphenylalaninemia:** 1:50.000 live births
- More common in whites

## Clinical Picture (Classic PKU)

- Normal at birth
- CNS: Seizures (25%), spasticity, tremors, microcephaly, MR "Normal mentality in 2-5%"
- Skin: Light complexion (*Blond, blue eyes*), seborrheic rash, eczema
- Vomiting

## Investigations

- Neonatal screening
  - Past: Bacterial inhibition test of Guthrie
  - Now: TMS
  - Time: In the 1<sup>st</sup> 48 hrs after protein intake is recommended
- Plasma phenylalanine
- EEG: Abnormalities in > 50%
- MRI & MRS:  $\uparrow\uparrow$  Phenylalanine
- Prenatal diagnosis is available (CVS)

## Treatment


- Phenylalanine restricted diet for **life**
  - Target level: 2-6 mg/dL
  - Phenylalanine deficiency: Lethargy, FTT, anemia, anorexia, diarrhea
  - Tyrosine becomes essential
- Oral BH<sub>4</sub> (10 mg/Kg/day):  $\downarrow\downarrow$  Phenylalanine level in 50% of cases



### **Maternal PKU**

**Mechanism:** Phenylalanine is teratogenic  
**C/P:** Microcephaly, MR, CHD

**Prevention:** Phenylalanine-restricted diet  
(Phe level should be < 6 mg/dL)





# **Hyperphenylalaninemia due to BH4 deficiency**

## **Biochemical Defect**

- BH4 is a cofactor for PAH, Tyrosine hydroxylase, Tryptophan hydroxylase & NO-synthase
- So, important in synthesis of dopamine & serotonin [Neurotransmitters]

## **Epidemiology**

- 1-3% of infants with hyperphenylalaninemia are due to defect in BH4 metabolism

## **Clinical Picture**

- Extrapyramidal: Choreoathetosis, dytonia, hypotonia (Diurnal variation)
- Seizures, MR
- Hyperprolactinemia (why?)

## **Investigations**

- Neonatal screening & plasma phenylalanine: Hyperphenylalaninemia
- BH4 loading test: ↓↓ plasma phenylalanine level
- ↓↓ CSF dopamine & serotonin
- Urinary biopterin
- Enzyme assay?? (Blood & liver)

## **Treatment**

- Phenylalanine restricted diet
- Oral BH4
- Neurotransmitters precursors: Dopa & tryptophan [Carbidopa should be given, why?]

## **BH4 deficiency without Hyperphenylalaninemia** **(= AD Dopa-responsive dystonia = Segawa syndrome)**

**Biochemical Defect** ↓↓ BH4 occurs due to GTP cyclohydrolase deficiency (AD form)

**Clinical Picture** Extrapyramidal: Dytonia starting in the LL (Diurnal variation)

## **Investigations**

- No Hyperphenylalaninemia,
- ↓↓ CSF dopamine
- Enzyme assay & gene analysis

**Treatment** Dopa [Carbidopa should be given]

# Tyrosinemia type I

## Definition

- AR
- Severe disease affecting liver, kidney & peripheral nerves

## Biochemical Defect

- ↓↓ Fumarylacetoacetate hydrolase → ↑↑ Succinylacetone → Organ damage

## Epidemiology

- 1:1000.000 live births (More common in those with French & Scandinavian ancestry)

## Clinical Picture (Onset = 2-6 months of age)

### A. Hepatic affection

- Fever, irritability, vomiting, hepatomegaly, jaundice, hypoglycemia, coagulopathy
- Boiled cabbage odor (↑↑ *Methionine*, why?)
- Liver cell failure, cirrhosis, hepatocellular carcinoma (> 2 yrs)

### B. Renal affection

- Proximal RTA
- Vitamin D-resistant rickets

### C. Peripheral neuropathy

- Pain, hypertonia, paralysis

## Investigations

- ↑↑ Blood & urine succinylacetone
- ↑↑ α-Fetoprotein (**Marked**)
- Investigation of liver, hematologic & renal affection: ALT, AST, bilirubin, glucose, CBC
- Plasma tyrosine level??
- Neonatal screening (succinylacetone)
- Prenatal diagnosis is available (AF succinylacetone or CVS)

## Treatment

- Phenylalanine & tyrosine restricted diet
- Nitisinone (NTBC):
  - Originally developed as a herbicide
  - Mechanism:
    - 2-Nitro-4-trifluoromethylbenzoyl-1,3-cyclohexanedione
    - Tyrosine corneal crystals may develop
- Liver transplantation



	<b>Tyrosinemia II (Oculocutaneous)</b>	<b>Tyrosinemia III</b>
<b>Defect</b>	↓↓ Tyrosine aminotransferase	↓↓ Hydroxyphenylpyruvate dioxygenase
<b>Genetics</b>	AR (16q)	AR (12q)
<b>C/P</b>	<ul style="list-style-type: none"><li>▪ <b>Skin:</b> Palmar &amp; plantar keratosis</li><li>▪ <b>Ocular:</b> Pain, redness, ↑↑ tears, ulcer</li><li>▪ <b>MR:</b> Mild</li></ul>	<ul style="list-style-type: none"><li>▪ Seizures, MR, ataxia</li><li>▪ Self mutilation</li></ul>
<b>Diagnosis</b>	<ul style="list-style-type: none"><li>▪ ↑↑ Plasma tyrosine</li></ul>	<ul style="list-style-type: none"><li>▪ ↑↑ Plasma tyrosine</li><li>▪ ↑↑ urine HPP</li></ul>
<b>TTT</b>	<ul style="list-style-type: none"><li>▪ Phenylalanine &amp; tyrosine restricted diet</li></ul>	<ul style="list-style-type: none"><li>▪ Diet + Vitamin C</li></ul>



# Alkaptonuria

## Definition

- AR (3q), rare (1:250.000)

## Biochemical Defect

- ↓↓ Homogentisic acid dioxygenase → ↑↑ Homogentisic acid → Tissue accumulation

## Clinical Picture

- The only sign of alcaptonuria in children is "**black urine on standing**"
- Ochronosis: Darkening of tissues (sclera & ear)
- Arthritis (big joints): Adult

## Investigations

- ↑↑ Urine homogentisic acid

## Treatment

- Phenylalanine & tyrosine restricted diet
- Nitisinone (NTBC)
- Vitamin C

# Transient Tyrosinemia of the Newborn

## Definition

- ↑↑ Tyrosine level in premature neonates (receiving ↑↑ protein diet)

## Biochemical Defect Immature HPPD → ↑↑ Tyrosine level

## Clinical Picture Lethargy, poor feeding, screening tests

## Investigations ↑↑ Plasma tyrosine & ↑↑ urine hydroxyphenylpyruvic acid

## Treatment Dietary protein restriction & Vitamin C

# Tyrosine Hydroxylase Deficiency

(= AR Dopa-responsive dystonia = Infantile Parkinsonism)

## Definition

- AR disease due to DOPA deficiency

## Biochemical Defect

- Tyrosine hydroxylase deficiency
- Tyrosine → DOPA

## Clinical Picture (as Segawa syndrome)

- Extrapyramidal: Dystonia, hypertonia, oculogyric crises, infantile parkinsonism
- No diurnal variation

## Investigations

- ↓↓ CSF dopamine

## Treatment

- Dopa [Carbidopa should be given]

# Albinism

## Definitions

- **Albinism:** Complete or partial absence of melanin pigment in the skin, hair & eyes
- **Melanocyte:** are melanin-producing cells located in skin (epidermis), eye & inner ear
- **Melanosome:** Organelle containing melanin
- **Melanin:** is a dark pigment present in skin, eye & hair (absorb UV rays)
- **Optical system development** is highly dependent on the presence of melanin

## Biochemical Defect

- Tyrosine → Melanin
- Types of melanin: **Pheomelanin** (yellow-red) & **Eumelanin** (Brown-black)
- Albinism may be Oculocutaneous (generalized), ocular or localized
- Albinism may be complete (No pigment at all) or partial

## Clinical Picture

### A. Skin affection

- Lack of skin pigment (Fair or white skin)
- ↑↑ Risk of sunburn & skin cancers

### B. Visual affection

- Photophobia, ↓↓ visual acuity, red reflex
- Nystagmus, squint, astigmatism, amblyopia "Poor transmission to the brain"
- Optic nerve hypoplasia, foveal hypoplasia
- Abnormal decussation of optic nerve fibres (abnormal VEP)

### C. Ear affection

- ↑↑ Susceptibility to ototoxic drugs

Treatment Avoid sun exposure & use of sunscreens (with high SPF)

## Oculocutaneous Albinism

	Defect	Manifestations	
<b>OCA1</b>	Tyrosinase deficiency	<b>OCA1A</b> (Severe)	<ul style="list-style-type: none"> <li>▪ Evident at birth &amp; persistent (remains unchanged)</li> <li>▪ Milky white skin, white hair, red gray eyes</li> <li>▪ No tan, No pigmented nevi</li> </ul>
		<b>OCA1B</b> (Mild)	<ul style="list-style-type: none"> <li>▪ Evident at birth &amp; improve with age</li> <li>▪ Light blond skin &amp; light blue eyes</li> <li>▪ Can develop pigmented nevi &amp; tan</li> </ul>
<b>OCA2</b>	Normal Tyrosinase	<ul style="list-style-type: none"> <li>▪ At birth: Some pigmentation &amp; ↑↑ with age (pigment accumulation)</li> <li>▪ Yellow hair, red gray eyes</li> <li>▪ Can develop pigmented nevi (Not tan)</li> <li>▪ <b>Prader-Willi &amp; Angelman</b> may have some ↓↓ pigments</li> </ul>	
<b>OCA3</b>		<ul style="list-style-type: none"> <li>▪ Reddish hair</li> <li>▪ Reddish brown skin</li> </ul>	
<b>OCA4</b>		<ul style="list-style-type: none"> <li>▪ Similar to OCA2</li> </ul>	
<b>Hermansky-Pudlak</b>		<ul style="list-style-type: none"> <li>▪ AR (Defect in melanosomes &amp; platelet dense bodies)</li> <li>▪ OCA, platelet dysfunction (why?)</li> </ul>	
<b>Chediak-Higashi</b>		<ul style="list-style-type: none"> <li>▪ Immunodeficiency, silvery hair, light skin</li> <li>▪ Defective degranulation (Neutropenia, platelet dysfunction)</li> </ul>	



## Ocular Albinism

- XLR
- Visual manifestation with **normal** skin pigmentation
- Late-onset sensorineural deafness has been reported

## Localized Albinism

### A. Piebaldism

- AD condition
- White forelock
- White macules on the face, trunk & extremities


### B. Waardenburg syndrome

- AD condition (2q, 3p), 4 types
- White forelock
- Broad nasal bridge, heterochromia, sensorineural deafness,

### C. Hypomelanosis of Ito

- Hypopigmentation following Blaschko's lines (*Invisible skin lines*)

## Methionine Metabolism



### Biochemical Defect

- Methionine is an essential amino acid
- Methionine catabolism: Methyl group donor & cysteine
- Most homocysteine is remethylated to methionine (catalyzed by methionine synthase)

## Homocystinuria

	<b>Homocystinuria</b>	<b>Marfan syndrome</b>
<b>Etiology</b>	Cystathionine synthase ↓↓	Defect in collagen fibers
<b>Inheritance</b>	AR	AD
<b>Mentality</b>	MR	Normal
<b>Muculoskeletal</b>	Arachnodactyly (2 Tests), Pectus excavatum, High arched palate, Kyphoscoliosis	The same + Hernias Pneumothorax
<b>Bone density</b>	Osteoporosis	Normal
<b>Joints</b>	Stiff	Lax
<b>Cardiovascular</b>	AR, MR	AR, MR, Aortic dissection
<b>Ocular</b>	Myopia Lens dislocation (Downwards)	Myopia Lens dislocation (Upwards)
<b>Vascular thrombosis</b>	↑↑ risk of thrombosis	No ↑↑ risk of thrombosis
<b>Investigations</b>	↑↑ Homocystine in urine	No ↑↑ Homocystine in urine
<b>Treatment</b>	Low methionine diet B6 & folic acid	Supportive

## Cysteine & Cystine Metabolism

### Cystinuria & Cystinosis

## Tryptophan Hartnup Disease

### Definition

- AR (5p), 1: 30.000
- Named after the 1<sup>st</sup> affected reported family

### Biochemical Defect

- Defective intestinal & renal transport of neutral amino acids
- ↓↓ Intestinal absorption of tryptophan → ↑↑ Indole derivatives → Blue diaper syndrome
- ↑↑ Renal excretion of tryptophan
- Tryptophan is essential for niacin synthesis → Niacin deficiency

### Clinical Picture (Pellagra-like)

- Skin: Cutaneous photosensitivity, rash, eczema
- CNS: Ataxia (intermittent), depression
- GIT: Glossitis

### Investigations

- Neonatal screening
- ↑↑ Urine **neutral** amino acids (Tryptophan, phenylalanine, tyrosine, alanine...)

**DD: Fanconi syndrome**

### Treatment Nicotinic acid



# Urea Cycle & Hyperammonemia

## Definition

- The function of urea cycle is to get rid of ammonia (Free  $\text{NH}_3$  is highly toxic)

## Biochemical Defect

- Five enzymes are involved in synthesis of urea:
    - Carbamyl phosphate synthetase (CPS)
    - Ornithine transcarbamylase (OTC)\*
    - Argininosuccinate synthetase (AS): **Citrullinemia**
    - Argininosuccinate lyase (AL): **Argininosuccinic aciduria**
    - Arginase: **Hyperargininemia**
    - N-acetylglutamate synthetase (*activator of CPS*)
- } All are AR except OTC

## Epidemiology

- 1: 30.000 live births
- Most common genetic cause of hyperammonemia

## Clinical Picture

### A. Neonatal period

- Normal at birth
- Poor feeding, vomiting, tachypnea
- Lethargy, coma, convulsions,  $\uparrow\uparrow$  ICT
- Hepatomegaly

Plasma  $\text{NH}_3$  should be done in any ill infant without evidence of infection

### B. Infants & older children

- Vomiting
- CNS: Ataxia, confusion, irritability (alternating with lethargy & coma)

## Investigations

- $\uparrow\uparrow\uparrow \text{NH}_3$  [Normal values:  $< 35$  (children),  $< 100$  (FT),  $< 150 \mu\text{mol/L}$  (Preterm)]
- $\downarrow\downarrow$  BUN,  $\uparrow\uparrow$  ALT, AST
- ABG: Respiratory alkalosis, why?
- Metabolites
  - CPS, OTC & NAG deficiency:  $\uparrow\uparrow$  Glutamine & alanine and  $\downarrow\downarrow$  arginine & citrulline
  - OTC deficiency:  $\uparrow\uparrow$  urinary orotic acid
  - Oral carbamylglutamate improve patients with NAG synthetase (Not CPS)
  - AS, AL, arginase deficiency:  $\uparrow\uparrow$  citrulline,  $\uparrow\uparrow$  argininosuccinic acid,  $\uparrow\uparrow$  arginine

### Inborn Errors of Metabolism causing Hyperammonemia:

- Urea cycle defects: 6 enzymes
- Organic acidemia
  - Methylmalonic acidemia
  - Propionic acidemia
  - Isovaleric acidemia
  - Multiple carboxylase deficiency
  - Beta-ketothiolase deficiency
  - 3-(OH)-3-methylglutaric aciduria
  - Glutaric aciduria type II
- Lysinuric protein intolerance
- Hyperammonemia-hyperornithinemia-homocitrullinemia syndrome
- Transient hyperammonemia of the newborn
- Congenital hyperinsulinism with hyperammonemia

## Treatment of Acute Hyperammonemia

### 1. Adequate Calories:

- IV fluid: electrolytes
- Glucose 10%
- Lipids: 1-2 g/Kg/day

**TTT of hyperammonemia should be rapid & aggressive ( $\text{NH}_3$  is toxic)**

### 2. Protein restriction

- Protein: 0.25 g/Kg/day
- Essential amino acids are preferred

### 3. Enhancement of ammonia excretion

- Priming dose (250 mg/Kg to be added to 20 mL/Kg G10% over 1-2 hrs) of:
  - Na benzoate: Removes  $\text{NH}_3$  in the form of hippuric acid
  - Phenylacetate: Removes  $\text{NH}_3$  in the form of phenylacetylglutamine
  - Arginine: Except in arginase deficiency
- Maintenance infusion (250 mg/Kg/day): Na benzoate, phenylacetate or arginine

### 4. Dialysis

- If there is no significant decrease of  $\text{NH}_3$
- Hemodialysis is preferred

### 5. Oral neomycin

- ↓↓ Intestinal production of  $\text{NH}_3$

### 6. Oral lactulose

- ↓↓ Intestinal absorption of  $\text{NH}_3$

## Long-Term Treatment of Hyperammonemia

### 1. Adequate Calories

### 2. Protein restriction

- Protein: 1-2 g/Kg/day

### 3. Enhancement of ammonia excretion

- Na benzoate
- Phenylacetate
- Arginine
- Citrulline: In OTC deficiency

### 4. Carnitine supplementation

### 5. Avoid triggering factors: Infections, fasting

### 6. Avoid valproate, why?

## **Transient Hyperammonemia of the newborn:**

### ▪ Blood ammonia in healthy neonates


- Blood ammonia is higher in neonates than adults
- Level may be up to 100  $\mu\text{mol/L}$  in FT neonates & 150  $\mu\text{mol/L}$  in preterm neonates
- Persists for few weeks
- Asymptomatic

### ▪ Severe Transient Hyperammonemia

- Unknown cause
- Usually preterm with RDS
- Level may be up to 4.000  $\mu\text{mol/L}$
- Rx of hyperammonemia



# Valine, Leucine & Isoleucine (& Related Organic Acidemias)



# Maple Syrup Urine Disease

## Definition

- AR Deficiency of branched-chain  $\alpha$ -ketoacid dehydrogenase (B1 is cofactor)
- 1: 185.000

## Biochemical Defect

- VIL (essential branched-chain amino acids)
- $\alpha$ -ketoacid dehydrogenase consists of 4 subunits ( $E_{1\alpha}$ ,  $E_{1\beta}$ ,  $E_2$ ,  $E_3$ ) coded by different genes
- $E_3$  is shared with other dehydrogenases (PDH,  $\alpha$ -ketoglutarate dehydrogenase)
- MSUD has 5 phenotypes: Classic, intermittent, mild, thiamine responsive &  $E_3$  deficiency

## Clinical Picture

- At birth: Normal
- First week: Poor feeding, vomiting, lethargy, coma, seizures, hypertonia, opisthotonos
- Peculiar odor: Maple syrup

## Investigations

- Neonatal screening
- Hypoglycemia, metabolic acidosis
- $\uparrow\uparrow$  VIL in plasma & urine
- CT: Brain edema
- Enzyme assay & gene analysis
- Prenatal diagnosis is available (enzyme or gene analysis)

Renal clearance of branched-chain aa is poor, so...

## Treatment

- Acute stage: Hydration, adequate calories, dialysis (PD or HD), mannitol, diuretics?
- After recovery: VIL restricted diet [ $\downarrow\downarrow$  VIL leads to C/P similar to acrodermatitis enteropathica]
- Liver transplantation

## Phenotypes of MSUD

	Classic MSUD	Intermittent MSUD	Mild MSUD	B1-responsive MSUD	$E_3$ subunit deficiency
Enzyme activity		20%	30%	40%	
Clinical Picture		Similar C/P occurs during stress or other catabolic conditions	Milder C/P Trial of B1 is recommended	Clinical & biochemical improvement with B1 (10-200 mg/d)	MSUD Lactic acidosis No effective Rx



# **Propionic Acidemia**

## **Definition**

- AR (13q & 3q)
- Deficiency of **propionyl-CoA carboxylase** (Biotin is cofactor)
- 1: 5.000 (in KSA)

## **Biochemical Defect**

- Propionyl-CoA carboxylase consists of 2 subunits ( $\alpha$  &  $\beta$ ) coded by 2 genes
- Cerebral atrophy & destruction of the BG (Metabolic stroke)

## **Clinical Picture**

- At birth: Normal
- First few days: Poor feeding, vomiting, lethargy, coma, seizures, hypotonia, acidosis
- Survivors develop recurrences triggered by infection, constipation or high-protein diet
- Older children: MR, dystonia

## **Investigations**

- Neonatal screening
- Metabolic acidosis (AG), ketosis, hypoglycemia, hyperammonemia (why?)
- **CBC:** Neutropenia, thrombocytopenia, anemia
- $\uparrow\uparrow$  Glycine (*Ketotic hyperglycinemia*)
- $\uparrow\uparrow$  Propionic acid in plasma & urine
- CT: Metabolic stroke
- Enzyme assay & gene analysis
- Prenatal diagnosis is available (enzyme or gene analysis)

## **Treatment**

### **A. Acute attack:**

- Hydration
- Adequate calories with protein restriction
- TTT of hyperammonemia
- GIT sterilization: Oral neomycin or metronidazole
- Carnitine supplementation
- Oral biotin (10 mg/day)
- Dialysis: PD or HD

### **B. Long-term management:**

- Adequate calories
- Protein restriction (Synthetic proteins deficient in propionic acid precursors are available?)
- Carnitine supplementation
- Chronic acidosis: alkali therapy
- Hyperammonemia?

# Methylmalonic Acidemia


## Definition

- AR
- Deficiency of **methylmalonyl-CoA mutase** or its coenzyme **adenosylcobalamin**
- 1: 48.000 (all forms)

## Biochemical Defect

- ↓↓ Methylmalonyl-CoA mutase may be  $\text{mut}^0$  (*absent activity*) or  $\text{mut}^-$  (*Decreased activity*)
- Seven defects in the intracellular metabolism of vitamin B12 (Cobalamin)
  - *cblA, cblB, cblD*  $\Rightarrow$  Adenosylcobalamin (MMA)
  - *cblC, cblF, cblD*  $\Rightarrow$  Adenosyl- & Methylcobalamin (MA & Homocystinuria)
  - *cblE, cblG, cblD*  $\Rightarrow$  Methylcobalamin (Homocystinuria)
- C/P due to  $\text{mut}^0$ ,  $\text{mut}^-$ , *cblA, cblB, cblD* are similar
- Cerebral atrophy & destruction of the BG (Metabolic stroke)

## Clinical Picture

- ...
-  ...
- **Complications:** CRF, neurological, acute & recurrent pancreatitis

## Investigations

- ↑↑ Methylmalonic acid in plasma & urine

## Treatment

### **A. Acute attack:**

- Vitamin B12 (1 mg/day)

### **B. Long-term management:**

- Liver transplantation, renal transplantation

# Isovaleric Acidemia

## Definition

- AR
- Deficiency of **isovaleryl-CoA dehydrogenase**
- 1: 100.000

## Clinical Picture

- Acute form: ...
- Chronic intermittent form: ...

## Investigations

- Neonatal screening
- Metabolic acidosis (AG), ketosis, hyperglycemia, hyperammonemia
- **CBC:** Neutropenia, thrombocytopenia, anemia
- ↑↑ Isovaleric acid in plasma & urine
- Enzyme assay & gene analysis
- Prenatal diagnosis is available (enzyme or gene analysis)

## Treatment

- Acute
- Long-term management



# Hyperoxaluria & Oxalosis

## Types

### ☒ Primary hyperoxaluria:

- Type I: Deficiency of alanine:Glyoxylate aminotransferase
- Type II: Deficiency of D-glycerate dehydrogenase

### ☒ Secondary hyperoxaluria:

- Pyridoxin deficiency
- High doses of vitamin C
- GIT cause: IBD, bowel resection
- Dietary: Spinach

## Primary Hyperoxaluria Type I

### Biochemical Defect

- Alanine:Glyoxylate aminotransferase is a peroxisomal enzyme
- The commonest mutation results in **mistargeting** of the enzyme to the mitochondria
- AR (2q)

### Clinical Picture

- Renal stones & nephrocalcinosis: Renal colics, hematuria, renal impairment
- Arthritis, crystalline retinopathy

### Investigations

- ↑↑ Urinary oxalate (also ↑↑ Glyoxylic & glycolic acid)
- Enzyme assay & gene analysis
- Prenatal diagnosis is available (enzyme or gene analysis)

### Treatment

- Pyridoxine especially in patients with...
- Combined liver & kidney transplantation

## Primary Hyperoxaluria Type II

### Biochemical Defect

- Deficiency of D-glycerate dehydrogenase
- AR (9cen)

### Clinical Picture

- Renal failure is less common

### Investigations

- ↑↑ Urinary oxalate (Normal urinary glyoxylic & glycolic acid)

### Treatment

- No effective TTT

# **Pyridoxine-Dependent Epilepsy**

## **Etiology**

- a. **Antiquitin deficiency\***: Enzyme in the catabolic pathway of lysine
- b. **Hypophosphatasia**: ALP is important for dephosphorylation of P5P

**Clinical Picture** Generalized intractable seizures (1<sup>st</sup> few hours)

**Investigations** EEG

**Treatment** Pyridoxine (5-100 mg/Kg): Dramatic response

**Trial of pyridoxine is recommended in any infant with intractable seizures**

# **Glutaric Aciduria Type I**

## **Definition**

- AR
- Deficiency of **Glutaryl CoA dehydrogenase enzyme** (Riboflavin is a cofactor)

## **Clinical Picture**

- **Macrocephaly**, hypotonia, loss of head control, seizures, dystonia, acidosis

## **Investigations**

- Neonatal screening
- Metabolic acidosis, ketosis, hypoglycemia, hyperammonemia
- ↑↑ Glutaric acid in urine, plasma & CSF
- Enzyme assay & gene analysis
- Prenatal diagnosis is available

## **Treatment**

- Protein restriction
- Riboflavin, L-carnitine, Strychnine & phenytoin: some benefit

# **Canavan Disease**

## **Etiology**

- AR disease (More prevalent in Jews)
- Deficiency of aspartoacylase enzyme (↑↑ N-acetylaspartic acid in CNS, blood & urine)

**Pathology** Spongy degeneration of the white matter

## **Clinical Picture**

- **Macrocephaly**, severe hypotonia followed by **hypertonia** & spasticity
- Joint stiffness & contractures
- Seizures, feeding difficulties, aspiration

**DD: CP**

## **Investigations**

- ↑↑ Urinary & CSF N-acetylaspartic acid
- **Enzyme assay**: aspartoacylase enzyme
- **MRI**: White matter degeneration in the cerebral hemispheres
- **MRS**: High peak of N-acetylaspartic acid


**Treatment** (No specific Rx)

- Trials of aspartoacylase




# **Fatty Acid Oxidation**

## **Carnitine Shuttle**



## **Steps of $\beta$ -FA oxidation**



**Acyl-CoA Dehydrogenase**

???

**Hydratase**

**Hydroxy  
Acyl-CoA Dehydrogenase**

**$\beta$ -Ketothiolase**

**Energy?**

## Importance of FA Oxidation

- Starvation, Relation to Ketogenesis
- ↓↓ Caloric intake (.....)
- Exercise
- Heart?
- Brain?

## Types of FA Oxidation

- ☒  $\beta$ -FA oxidation
- ☒  $\alpha$ -FA oxidation
- ☒ Peroxisomal FA oxidation

## General C/P of FA Oxidation

- Inheritance: All are AR
  - Incidence: FA oxidation disorders combined are common
  - May be asymptomatic?
  - Organs affected?
    - **Liver:** Hypoketotic hypoglycemia, coma (ALTE)
    - **Skeletal muscles:** Exercise intolerance & exercise-induced rhabdomyolysis
    - **Heart:** Cardiomyopathy
    - **Kidneys:** RTA
  - Other manifestations
    - **Fatty liver of pregnancy or preeclampsia with HELLP:**
      - When? Fetus , Mother
      - HELLP: Hemolysis, Elevated liver enzymes, Low platelet count
      - Mechanism: Related to toxic effect of FA rather than...
      - Types: LCHAD, TFP, CPT-1 deficiency
    - **Congenital malformations (Brain & Kidneys):**
      - Mechanism: Related to toxic effect of FA rather than...
      - Types: ETF, ETF-DH, CPT-II
    - **Pigmented retinopathy**
    - **Progressive liver disease**
    - **Peripheral neuropathy**
- } *LCHAD/TFP deficiency*
- The only specific clue for diagnosis is **hypoketotic hypoglycemia**
  - Neonatal screening: characteristic acylcarnitines
  - DD: Reye syndrome, SIDS



# Peroxisomal Disorders

## Classification

### A. Peroxisomal biogenesis defects:

- Failure to import one or more proteins into the peroxisomes
- Peroxisomes: Absent or decreased
- Abnormalities of multiple peroxisomal functions are present
- Disorders:

- ☒ Zellweger syndrome (ZS)
  - ☒ Neonatal adrenoleukodystrophy (NALD)
  - ☒ Infantile Refsum disease (IRD)
  - ☒ Rhizomelic chondrodysplasia punctata (RCDP)
- } *Zellweger spectrum disorders*

### B. Single enzyme defect

- Defect in the function of a single peroxisomal enzyme
- Peroxisomes: Normal number & structure
- Abnormality of single peroxisomal function
- Disorders:

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> X-linked adrenoleukodystrophy   | <input checked="" type="checkbox"/> Mevalonic aciduria         |
| <input checked="" type="checkbox"/> Acyl CoA oxidase deficiency     | <input checked="" type="checkbox"/> Glutaric aciduria type III |
| <input checked="" type="checkbox"/> Peroxisomal thiolase deficiency | <input checked="" type="checkbox"/> Hyperoxaluria type I       |
| <input checked="" type="checkbox"/> Classic Refsum disease          | <input checked="" type="checkbox"/> Acatalasemia               |

## Epidemiology

- 1:50.000 live births
- X-ALD is the commonest (1:20.000)
- All are AR except...
- Antenatal diagnosis is available

## Pathology

- PBD: Absent or decreased peroxisomes with peroxisome "Ghosts"
- Multisystem affection:
  - a. **Nervous system:** Defect in neuronal migration, MR, hypotonia
  - b. **Liver:** Hepatomegaly, cirrhosis
  - c. **Skeletal:** Chondrodysplasia punctata
  - d. **Eye:** Cataract, glaucoma, retinopathy
  - e. **Heart:** CHD
  - f. **Dysmorphic features**

Mechanism?

## Refsum Neuropathy

Etiology AR<sup>10</sup> (Phytanoyl CoA oxidase)

Pathogenesis Failure of  $\alpha$ -FA oxidation → accumulation of phytanic acid

C/P Polyneuropathy, ataxia, retinitis pigmentosa, blindness, deafness, ichthyosis (scaly skin)

Investigations ↑↑ Serum phytanic acid, ↓↓ NCV

Treatment ↓↓ Dietary phytanic acid (nuts, coffee)  
Plasmapheresis

# **Zellweger Syndrome**

## **Genetics**

- AR; most common cause are mutation in PEX1 & PEX6

DD?

## **Clinical Picture**

- Dysmorphic facies: high forehead, hypoplastic supraorbital ridges, epicanthal folds, midfacial hypoplasia, large fontanel
- Ocular: Cataract, glaucoma, corneal clouding, brush-field spots, nystagmus, optic nerve hypoplasia, pigmentary retinopathy
- Hypotonia, seizures, psychomotor retardation, sensorineural deafness
- Hepatomegaly, cholestasis, cirrhosis
- Renal cysts

# **Neonatal Adrenoleukodystrophy**

## **Genetics**

- AR, mutation in PEX genes (e.g., PEX1...)

## **Clinical Picture**

- Dysmorphic facies: Few or absent
- Ocular: Pigmentary retinopathy
- Hypotonia, seizures, psychomotor retardation, sensorineural deafness
- Hepatomegaly, cholestasis, cirrhosis
- Adrenal function is usually impaired

# **Infantile Refsum Disease**

## **Genetics**

- AR, mutation in PEX genes (e.g., PEX1...)

## **Clinical Picture**

- Dysmorphic facies: Few or absent
- Ataxia (broad based gait)
- Ocular: Pigmentary retinopathy
- Hypotonia, seizures, **psychomotor retardation**, sensorineural deafness
- Hepatomegaly, cholestasis, cirrhosis

# **Rhizomelic chondrodysplasia Punctata**

## **Genetics**

- AR, mutation of PEX7 (receptor for PTS2)

## **Clinical Picture**

- Disproportionate short stature (Rhizomelic = )
- Dysmorphic facies: Depressed nasal bridge, hypertelorism
- Cataract, psychomotor retardation, ichthyosis, quadriplegia (why?)

## **Investigations**

- Radiology: epiphyseal stippling, vertebral body clefts





## **Approach to Diagnosis of Peroxisomal Disorders**

### **A. Level 1: Confirm the diagnosis of peroxisomal disorder**

- VLCFA: ↑↑ (Normal in RCDP)
- Phytanic acid
- Pipecolic acid
- RBC plasmalogen
- Bile acids

### **B. Level 2: Precise nature of the peroxisomal disorder**

Disorder	VLCFA	RBC plasmalogen	Pipecolic acid	Phytanic acid	Bile acid
ZS, NALD, IRD	↑↑	↓↓	↑↑	↑↑	↑↑
RCDP	N	↓↓	N	↑↑	N
Classic Refsum	N	N	N	↑↑	N
X-ALD	↑↑	N	N	N	N
Bifunctional enzyme	↑↑	N	N	↑↑	↑↑

### **C. Level 3: Molecular defect of peroxisomal disorder: PEX genes**

#### **Treatment**

- Classic Refsum disease:
- Supportive TTT
- Oral docosahexaenoic acid

# Adrenoleukodystrophy

## Definition

- Peroxisomal disorder characterized by accumulation of VLCFA in CNS & adrenal cortex
- Neonatal ALD & XL-ALD

## XL-Adrenoleukodystrophy

### Etiology

- Defect in peroxisomal degradation of VLCFA (Due to  $\downarrow\downarrow$  **lignoceroyl CoA ligase**)
- Accumulation of VLCFA in CNS & adrenal cortex
- Not rare; 1:20.000 ♂

### Pathogenesis

- Accumulation of VLCFA  $\rightarrow$  adrenal dysfunction
- CNS: Inflammation (Demyelination); mostly in the parieto-occipital area

### Clinical Picture "Five phenotypes are recognized"

#### A) Childhood cerebral form

- Onset: 4-8 years
- Hyperactivity (DD: ADHD), academic deterioration
- Impaired auditory discrimination, visual disturbance, ataxia
- Seizures, spastic quadriparesis
- Bulbar manifestations
- $\uparrow\uparrow$  ICT, unilateral mass lesion
- **Adrenal insufficiency:** Usually follows but may precedes neurologic manifestations

#### B) Adolescent ALD: Delayed onset & less progressive course

#### C) Adrenomyeloneuropathy

- Affection of spinal cord & peripheral nerves in adolescents & adults
- Progressive paraparesis, urinary incontinence, impotence

#### D) Addison only: 25% of Addison patients have biochemical defects of ALD, so...

#### E) Asymptomatic ALD

NB: 50% of heterozygous ♀ may have milder adrenomyeloneuropathy

### Investigations

- $\uparrow\uparrow$  VLCFA in plasma, RBC, fibroblasts
- CT, MRI: Typically symmetric periventricular in the posterior parietal & occipital lobes  
Unilateral lesion with mass effect (DD: Tumor) may occur
- Adrenal function tests: ACTH, cortisol after ACTH stimulation

### Treatment

- BMT: Considered in neurologically asymptomatic or mildly affected patients
- Lorenzo's oil:  $\downarrow\downarrow$  VLCFA synthesis
- Adrenal replacement

### Prevention & Genetic counseling



- **Family screening:** VLCFA (allows early diagnosis of presymptomatic individuals, why?)
- **Antenatal diagnosis:** VLCFA (amniocytes or CVS) or molecular testing
- Addison males

DD ADHD, other leukodystrophies, MS, brain tumors, epilepsy, Addison





# **Lysosomal Disorders**





# Sphingolipidosis

## Definition

- Group of diseases characterized by accumulation of sphingolipids
- Sphingolipids: Sphingosine-containing lipids (*Cerebrosides, gangliosides*)
- Sphingosine is an amino alcohol

## **Sphingolipidosis**

### **Sphingolipidosis:**

1. GM 1 Gangliosidosis
2. GM 2 Gangliosidosis
3. Krabbe disease (KD)
4. Metachromatic LD
5. Gaucher
6. Niemann-Pick

### **Other Sphingolipidosis:**

1. Fabry
2. Farber
3. Wolman
4. Multiple sulfatase deficiency

## Gaucher Disease

### Etiology

- Glucocerebrosidase ( $\beta$ -Glucosidase) deficiency (AR<sup>1</sup>)
- **Four** mutations account for the majority of cases
- Incidence in Jews = 1/1.000
- Carrier rate in Jews = 1/18

**Gaucher should be considered in the DD of any child with unexplained organomegaly**

### Clinical Picture

	<b>Type 1* (99%)</b>	<b>Type 2</b>	<b>Type 3</b>
<b>Other Names</b>	Adult type Non-Neuropathic	Infantile Acute neuropathic	Juvenile Subacute neuropathic
<b>Onset</b>	Variable	Infancy	Early childhood > 2yrs
<b>C/P</b>	<ul style="list-style-type: none"> <li>▪ HSM (S &gt; L)</li> <li>▪ Anemia</li> <li>▪ Thrombocytopenia</li> <li>▪ Bruises</li> <li>▪ Bony pains</li> <li>▪ Pathologic fractures</li> <li>▪ Normal mentality (?? Chronic disease)</li> </ul>	<ul style="list-style-type: none"> <li>▪ HSM</li> <li>▪ Hypertonia</li> <li>▪ Head retraction</li> <li>▪ Laryngospasm</li> <li>▪ Stridor</li> <li>▪ Squint</li> <li>▪ Cranial nerve...</li> <li>▪ Rapid <b>neurologic</b>...MR</li> <li>▪ Death in the 1<sup>st</sup> 2 yrs</li> </ul>	<ul style="list-style-type: none"> <li>▪ HSM</li> <li>▪ <b>Neurologic</b> (Less severe)</li> <li>▪ MR</li> <li>▪ Ataxia</li> <li>▪ Myoclonic epilepsy</li> <li>▪ Gaze palsy</li> <li>▪ Death by age of 10-15 y</li> </ul>

### Investigations

- X-rays: Lytic lesions, Erlenmeyer flask deformity (Distal femur)
- BM examination: Gaucher cells (Positive PAS stain)
- Enzyme assay: Leukocytes or fibroblast
- Carrier detection: Molecular testing (4)
- Antenatal diagnosis is available

**Not Pathognomonic**

### Treatment

- Enzyme replacement: Cerezyme (IV infusion every other week): No effect on CNS
- BMT
- Gene therapy



# Niemann-Pick Disease

## Etiology

- Type A & B: Sphingomyelinase deficiency (AR<sup>11</sup>)
- Type C: Defective cholesterol transport (with 2ry sphingomyelinase deficiency)

## Clinical Picture

	Type A	Type B	Type C
Other Names	Acute infantile	Non-Neuropathic	Neuropathic
Onset	1 <sup>st</sup> few months of life	Infancy or childhood	Early childhood > 2yrs
C/P	<ul style="list-style-type: none"> <li>▪ HSM (L &gt; S)</li> <li>▪ FTT, feeding difficulties</li> <li>▪ Neurological...MR</li> <li>▪ Cherry-red spots (50%)</li> <li>▪ Spasticity</li> <li>▪ Death in the 1<sup>st</sup> 3 yrs</li> </ul>	<ul style="list-style-type: none"> <li>▪ HSM</li> <li>▪ Pulmonary involvement</li> <li>▪ Dyspnea, pneumonia</li> <li>▪ No neurological...</li> <li>▪ Normal mentality</li> <li>▪ Hypersplenism</li> </ul>	<ul style="list-style-type: none"> <li>▪ Ataxia</li> <li>▪ Slowly progressive neurologic course</li> <li>▪ Gaze palsy</li> <li>▪ HSM (<i>Less severe</i>)</li> </ul>

## Investigations

- BM examination: Foam cells (NP cells)
- Enzyme assay (Leukocytes or fibroblasts)
- CXR (Type B): Reticular or nodular infiltration
- Antenatal diagnosis is available

## Treatment

- Supportive
- Liver transplantation
- Enzyme therapy in type B (Phase I trial)

# Farber Disease

## Etiology

- Ceramidase deficiency (AR)
- Accumulation of ceramide in various tissues, especially the joints

## Clinical Picture


- Onset: 1<sup>st</sup> year of life
- Joint: Painful swelling & nodules
- Vocal cord nodules: Hoarseness of voice

## Investigations

- Enzyme assay (Leukocytes or fibroblasts)
- Antenatal diagnosis & carrier detection is available

## Treatment

- Supportive



# Fabry Disease

(See before)

# Gangliosidosis

**Definition** Accumulation of gangliosides (Glycosphingolipids)

## GM1 Gangliosidosis

### Etiology

-  $\beta$ -Galactosidase deficiency (AR<sup>3</sup>) → Accumulation of GM1 gangliosides (CNS & visceral)

### Clinical Picture

	Infantile*	Juvenile	Adult
Other Names	Type 1	Type 2	Type 3
Onset	Birth	1 year	Adult
C/P	<ul style="list-style-type: none"> <li>▪ Poor feeding</li> <li>▪ HSM</li> <li>▪ Global developmental delay</li> <li>▪ Seizures</li> <li>▪ Spasticity</li> <li>▪ Hurler-like...</li> <li>▪ Dysostosis multiplex</li> <li>▪ Blindness &amp; Deafness</li> <li>▪ Cherry-red spots</li> <li>▪ Angiokeratoma</li> <li>▪ Death in the 1<sup>st</sup> 3 yrs</li> </ul>	<ul style="list-style-type: none"> <li>▪ Ataxia</li> <li>▪ Mental retardation</li> <li>▪ Seizures</li> <li>▪ Spasticity</li> <li>▪ Blindness</li> <li>▪ No HSM</li> <li>▪ No Hurler-like...</li> <li>▪ Death in the 1<sup>st</sup> 10 yrs</li> </ul>	<ul style="list-style-type: none"> <li>▪ Ataxia</li> <li>▪ Spasticity</li> <li>▪ Dysarthria</li> <li>▪ ↓↓ Cognitive function</li> </ul>

## GM2 Gangliosidosis

### Etiology

- Tay-Sachs: AR<sup>15</sup> Sandhoffs: AR<sup>5</sup>
- Carrier rate of Tay-Sachs in Jews = 1/25

### Clinical Picture

	Tay-Sachs	Sandhoff	Juvenile & Adult
Genetics	HEXA gene (Chromosome 15)	HEXB gene (Chromosome 5)	-
Defect	Hexosaminidase A	Hexosaminidase A & B	
Onset	5-6 months		Childhood-adult
C/P	<ul style="list-style-type: none"> <li>▪ Marked startle reaction (= Hyperacusis)</li> <li>▪ Regression</li> <li>▪ No HSM</li> <li>▪ Seizures</li> <li>▪</li> </ul>	<ul style="list-style-type: none"> <li>▪ Early hypotonia → Spasticity</li> <li>▪ Blindness &amp; Deafness</li> <li>▪ Macrocephaly</li> <li>▪ Cherry-red spots</li> <li>▪ Death in the 1<sup>st</sup> 3-5 yrs</li> </ul> <p><b>Splenomegaly (HSM) in Sandhoff</b></p>	<ul style="list-style-type: none"> <li>▪ Ataxia</li> <li>▪ Spasticity</li> <li>▪ Dysarthria</li> </ul>

### Investigations

- Enzyme assay: Leukocytes or fibroblast
- Antenatal diagnosis & carrier detection is available (Enzyme activity)

**Treatment** Supportive

### **Macroglossia:**

1. MPS
2. Gangliosidosis
3. Hypothyroidism
4. BW syndrome
5. Fucosidosis



# **Krabbe Disease**

(Globoid Cell Leukodystrophy)

## **Etiology**

- Galactocerebroside  $\beta$ -Galactosidase deficiency (AR)
- Accumulation of Galactocerebroside  $\rightarrow$  Myelin destruction (Vicious circle)

## **Clinical Picture**

- Onset: 1<sup>st</sup> months of life
- Irritability, crying, spasticity, opisthotonos, Seizures
- Neuropathy, absent deep reflexes

(DD: Colic, milk allergy...)

## **Investigations**

- Enzyme assay (Leukocytes or fibroblasts)
- Antenatal diagnosis & carrier detection is available

## **Treatment**

- Stem cell transplantation may improve the outcome if given very early

# **Metachromatic Leukodystrophy**

## **Etiology**

- Arylsulfatase deficiency (AR<sup>22</sup>)
- Accumulation of cerebroside sulfate  $\rightarrow$  Myelin destruction (*CNS & peripheral nerves*)
- Classified into: Late infantile, juvenile & adult types

## **Clinical Picture**

- Onset: 1-2 year
- Regression (Loss of ability to walk...)
- Hypotonia, Seizures
- Neuropathy, absent deep reflexes

## **Investigations**

- $\downarrow\downarrow$  NCV,  $\uparrow\uparrow$  CSF proteins
- Enzyme assay (Leukocytes or fibroblasts)
- Antenatal diagnosis & carrier detection is available

## **Treatment**

- Stem cell transplantation may improve the outcome if given very early

# **Wolman Disease**

**Etiology** Acid lipase deficiency (AR)  $\rightarrow$  Accumulation of cholesterol esters

**Clinical Picture** FTT + Steatorrhea + HSM + Calcification of the adrenal glands

# **Neuronal Ceroid Lipofuscinosis**

## **Definition**

- Lysosomal storage disorder
- Intracellular accumulation of fluorescent lipopigments, ceroid & lipofuscin
- NCL is characterized by visual loss, seizures, motor deterioration & early death
- Traditionally classified into: Infantile, Late infantile & juvenile types

# Mucopolysaccharidosis

## Biochemistry

☒ **Monosaccharide:** Glucose, Galactose, Fructose

☒ **Disaccharide:** Maltose, Lactose, Sucrose

☒ **Polysaccharide:**

- Homo-: Glycogen, Starch, Inulin, Agar
- Hetero-: Glycosaminoglycans (= MPS)

### **GAG:**

- Chondroitin sulfate
  - Dermatan sulfate
  - Keratan sulfate
  - Heparan sulfate (*CNS*)
  - Hyaluronic acid
- } (*CT*)

## Definition

- Lysosomal inherited disorders caused by incomplete degradation & storage of GAG
- **MPS-III** is the most common followed by MPS-I & II
- Incidence = 4: 100.000

## Mode of Inheritance

All are AR except Hunter (Type II)

## Clinical Picture

- Normal at birth, Why???
- Progressive course
- Nasal discharge
- All have corneal Clouding except...
- Deafness in Type...
- Hernia (Recurrent)
- Main organs: Bones, Cartilages, Joints, Tendons, CT, Skin, CNS

## Classification

With...	Without...
Hurler syndrome (Type I-H)	Morquio syndrome (Type IV)
Hunter syndrome (Type II)	Scheie syndrome (Type V = Type I-S)
Sanfilippo syndrome (Type III)	Maroteaux-Lamy syndrome (Type VI)

- **Sly disease (Type VII):** Wide range of clinical involvement (Fetal hydrops- delayed onset)
- **Type IX:** Periarticular soft tissue masses & short stature

## Dysostosis Multiplex

- Radiological changes
- Features
  - Skull: Macrocephaly, Dolicocephaly, J-shaped sella turcica
  - Clavicles: Thickening of the medial 1/3
  - Ribs: Spatulated (oar-shaped)
  - Vertebrae: Ovoid with anterior beaking
  - Iliac bones: Flaring
  - Radius & Ulna: Abnormal with V-shaped articulation
  - Metacarpals: Pointed proximally (5<sup>th</sup>\*)
  - Phalanges: Pointed distally (bullet-shaped)

## Diagnosis

☒ **Clinical**

☒ **Radiological:** Dysostosis multiplex

☒ **Urinary GAG**

☒ **Enzyme assay** (Serum, WBC, Fibroblasts):  $\alpha$ -L-Iduronidase in MPS-I-H



## MPS-I

### Hurler Syndrome

1. **At birth:** Normal (Diagnosis is usually made between 6-24 months)
2. **1<sup>st</sup> year:**
  - Persistent nasal discharge & obstruction
  - MR, HSM, Kyphosis
3. **After the 1<sup>st</sup> year**
  - Nasal discharge, MR, HSM, Kyphosis
  - Obstructive airway disease (OSA)
  - Coarse facies: Coarse hair, large head, hypertelorism, depressed nasal bridge, low-set ears, macroglossia, thick lips
  - Cardiac: Cardiomyopathy, coronary stenosis, valvular affection (AR, MR)
  - Hydrocephalus (Communicating)
  - Skeletal: Joint stiffness, claw hand, kyphosis, hernia, X-rays (Dysostosis multiplex)

$\alpha$ -L-Iduronidase

Most severe

### Scheie Syndrome

1. Previously called Type V
2. C/P appears after the age of 5 years
3. Corneal clouding
4. Claw hand
5. Carpal tunnel syndrome
6. Aortic regurgitation
7. Normal mentality

Mildest

5

### MPS-II Hunter Syndrome

1. As Hurler but milder
2. XLR, No Corneal clouding
3. Deafness
4. Hydrocephalus
5. Skin papules

Iduronate-2- sulfatase

XLR الوحيد  
No corneal clouding الوحيد

### Sanfilippo Syndrome

1. Rapid neurological deterioration
2. Severe MR
3. Mild dysmorphism

Neurological

### Morquio Syndrome

1. Short stature
2. Skeletal: Kyphosis, flat feet, genu valgum, platyspondyly
3. HSM, corneal clouding...
4. Small separated teeth, broad mouth
5. Atlant-oaxial instability

Skeletal

$\beta$ -Galactosidase


### Maroteaux-Lamy Syndrome

1. As Hurler but delayed onset & slower course
2. Normal mentality

Arylsulfatase B

No MR

## Clinical Approach to a case of MPS



### Regular Assessment

- ☒ General history & examination
- ☒ Audiometry
- ☒ Visual acuity, corneal & retinal examination
- ☒ FVC & sleep study
- ☒ ECG, Echo

### Treatment

- ☒ HSCT: MPS I, II, VI
- ☒ Enzyme replacement: HSCT: MPS I, II, VI
- ☒ Combined
- ☒ Multidisciplinary care

### **Hurler-like Diseases:**

1. GM 1 Gangliosidosis
2. Mucopolipidosis
3. Fucosidosis
4. Sialidosis type II
5. Mannosidosis



# **Glycogen Storage Diseases**

## **Types**

<b>Disease</b>	<b>Enzyme Defect</b>	<b>Clinical Picture</b>
<b>Type Ia</b> (Von Gierke)	G-6-Phosphatase	Doll face Marked Hepatomegaly Fasting hypoglycemia (Seizures) Hypercholesterolemia Lactic acidosis ↑↑ Uric acid
<b>Type Ib</b>	G-6-Phosphate Translocase	GSDI + Neutropenia
<b>Type II</b> (Pompe)	Acid maltase	Hepatomegaly Myopathy Cardiomyopathy
<b>Type III</b> (Cori)	Debranching	Hepatomegaly Hypoglycemia Myopathy
<b>Type IV</b> (Andersen)	Brancher	HSM Liver cirrhosis LCF Ascites
<b>Type V</b> (Mc Ardle)	Muscle Phosphorylase	Exercise intolerance Muscle cramps Easy fatigability
<b>Type VI</b> (Hers)	Liver Phosphorylase	
<b>Type VII</b> (Tauri)	PFK	V + Hemolytic anemia
<b>Type VIII</b>		??Ataxia
<b>Type IX</b>	Phosphoglycerate Kinase	
<b>Type X</b>		
<b>Type XI</b> (Fanconi-Bickel)	Glucose Transporter II	FTT + Fanconi + Hepatomegaly
<b>Type 0</b>	Glycogen synthase	Fasting hypoglycemia (Seizures) Prolonged hyperglycemia (after meals)

## **Diagnosis**

- Biochemical
- Liver biopsy
- Enzyme assay (Liver)

## **Treatment**

- Avoid...
- Enzyme?
- Liver transplantation

<b>Hepatic</b>	<b>Muscle</b>	<b>Mixed</b>

# **Galactosemia**

## **Etiology**

1. Galactose 1-P-uridyltransferase deficiency\*\* (Classic Galactosemia)
2. Galactokinase deficiency (Only cataract)
3. Epimerase deficiency

## **Clinical Picture**

- Jaundice (Cholestasis)
- Hepatomegaly, splenomegaly, ascites
- Hypoglycemia, convulsions, lethargy
- FTT, vomiting
- Cataract
- E.coli sepsis

## **Diagnosis**


- Reducing substances in urine (When?)
- Enzyme assay

## **Treatment**

# **Hereditary fructose intolerance**



## Clinical Approach



# Urea Cycle

